D. Rimm

R. Herbst, A. Chiang, D. Zelterman, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Antibody validation for protein expression on tissue slides: a protocol for immunohistochemistry

D. Rimm, J. Zugazagoitia, Tyler MacNeil, 2020, BioTechniques.

Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.

I. Wistuba, J. Lee, S. Swisher, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Immune Checkpoint Inhibitor-Associated Pericarditis.

R. Herbst, D. Rimm, S. Gettinger, 2019, Journal of Thoracic Oncology.

Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms

D. Rimm, K. Ikenberg, J. Wilmott, 2022, EBioMedicine.

High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis

K. Fu, Zenggang Pan, D. Rimm, 2021, Frontiers in Oncology.

Immunohistochemical Biomarkers in Patients with Early‐Onset Breast Carcinoma by Tissue Microarray

D. Rimm, B. Haffty, D. Carter, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non–Small Cell Lung Cancer

Anagha P. Jadhav, Clive R. Taylor, A. Gown, 2019, Applied immunohistochemistry & molecular morphology : AIMM.

PECAM-1 ( CD 31 ) functions as a reservoir for and a modulator of tyrosine-phosphorylated β-catenin

D. Rimm, S. Mahooti, N. Ilan, 1999 .

Detection of chromosomal instability in paired breast surgery and ductal lavage specimens by interphase fluorescence in situ hybridization.

D. Ward, D. Rimm, L. Morrison, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Andrew H. Beck, Jacqueline A. Hall, A. Beck, 2020, npj Breast Cancer.

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Jacqueline A. Hall, Sarah N. Dudgeon, A. Gown, 2020, npj Breast Cancer.

Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer

L. Pusztai, T. Qing, D. Rimm, 2022, NPJ breast cancer.

Met, the hepatocyte growth factor receptor, localizes to the nucleus in cells at low density.

D. Rimm, D. Pappas, Sharon Pozner-Moulis, 2006, Cancer research.

Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study

A. Gown, S. Leung, T. Nielsen, 2022, Modern Pathology.

Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers

P. Hegde, L. Pusztai, D. Rimm, 2020, Journal for ImmunoTherapy of Cancer.

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer

L. Pusztai, T. Qing, D. Rimm, 2021, NPJ breast cancer.

Quantitative Assessment of CD200 and CD200R Expression in Lung Cancer

K. Syrigos, D. Rimm, J. Zugazagoitia, 2021, Cancers.

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.

I. Wistuba, S. Swisher, R. Herbst, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Quantitative evaluation of protein expression as a function of tissue microarray core diameter: is a large (1.5 mm) core better than a small (0.6 mm) core?

K. Syrigos, D. Rimm, V. Anagnostou, 2010, Archives of pathology & laboratory medicine.

Polymerase chain reaction‐based detection of clonality as a non‐morphologic diagnostic tool for fine‐needle aspiration of the breast

D. Rimm, J. Magda, B. A. Minger, 1998, Cancer.

Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer

Yan Song, D. Rimm, K. Bloom, 2022, Laboratory Investigation.

Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer

R. Herbst, D. Rimm, K. Schalper, 2022, Journal for ImmunoTherapy of Cancer.

A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome

E. Rimm, D. Rimm, R. Camp, 2000, Cancer.

Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non–Small Cell Lung Cancer

D. Rimm, K. Schalper, A. Psyrri, 2021, Clinical Cancer Research.

Digital quantitative assessment of PD-L1 using digital spatial profiling

D. Rimm, J. Zugazagoitia, Swati Gupta, 2020, Laboratory Investigation.

Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer

Yan Song, D. Rimm, K. Bloom, 2022, Laboratory Investigation.

Oropharyngeal squamous cell cancers (OSCC) bearing transcriptionally active human papillomavirus (HPV) display distinct protein expression profile.

D. Rimm, R. Camp, A. Psyrri, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imaging, Diagnosis, Prognosis Comparative Prognostic Value of Epidermal Growth Factor Quantitative Protein Expression Compared with FISH for Head and Neck Squamous Cell Carcinoma

D. Rimm, A. Psyrri, P. Kountourakis, 2011 .

Comparison of the costs of fine‐needle aspiration and open surgical biopsy as methods for obtaining a pathologic diagnosis

E. Rimm, W. Frable, D. Rimm, 1997, Cancer.

A mutation in alpha-catenin disrupts adhesion in clone A cells without perturbing its actin and beta-catenin binding activity.

D. Rimm, S. Roe, E. R. Koslov, 1998, Cell adhesion and communication.

Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer

R. Herbst, D. Rimm, S. Langermann, 2022, Laboratory Investigation.

Association between low estrogen receptor positive breast cancer and staining performance

D. Rimm, Emily S. Reisenbichler, Dennis Caruana, 2020, npj Breast Cancer.

BRIEF REPORT: Immune checkpoint inhibitor associated pericarditis

R. Herbst, D. Rimm, S. Gettinger, 2019 .

PD05-03: Impact of Quantitative Measurement of HER2, HER3, HER4, EGFR, ER and PTEN Protein Expression on Benefit to Adjuvant Trastuzumab in Early-Stage HER2+ Breast Cancer Patients in NCCTG N9831.

S. Martino, G. Sledge, L. Harris, 2011 .

p53 Mutations as Tumor Markers in Fine Needle Aspirates of Palpable Breast Masses

D. Rimm, D. Dillon, José Costa, 2002, Acta Cytologica.

The value of onsite adequacy assessment of thyroid fine‐needle aspirations is a function of operator experience

D. Rimm, Mohiedean Ghofrani, D. Beckman, 2006, Cancer.

BRCA Status, Molecular Markers, and Clinical Variables in Early, Conservatively Managed Breast Cancer

D. Rimm, B. Haffty, D. Carter, 2003, The breast journal.

Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma

D. Rimm, R. Camp, H. Kluger, 2010, Clinical Cancer Research.

Molecular cloning of human E-cadherin suggests a novel subdivision of the cadherin superfamily.

J. S. Morrow, D. Rimm, 1994, Biochemical and biophysical research communications.

The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization

S. Ariyan, D. Rimm, M. Sznol, 2007, Journal of Translational Medicine.

Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex.

D L Rimm, J. S. Morrow, D. Rimm, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Molecular Cloning Reveals Alternative Splice Forms of Human α(E)-Catenin

J. S. Morrow, D. Rimm, P. Kebriaei, 1994 .

Quantification of hormone receptors to guide adjuvant therapy choice in early breast cancer: better methods required for improved utility.

D. Rea, D. Rimm, J. Bartlett, 2011, Journal of Clinical Oncology.

Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer

R. Herbst, D. Rimm, K. Schalper, 2022, Journal for ImmunoTherapy of Cancer.

Analysis of cDNA clones for Acanthamoeba profilin-I and profilin-II shows end to end homology with vertebrate profilins and a small family of profilin genes.

T. Pollard, D. Rimm, 1991, Cell motility and the cytoskeleton.

PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.

D. Rimm, A. Psyrri, P. Economopoulou, 2021, Oral oncology.

In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis.

S. Agarwal, J. Bordeaux, D. Rimm, 2010, The American journal of pathology.

Macrophage expression of tartrate-resistant acid phosphatase as a prognostic indicator in colon cancer

D. Rimm, Jason R. Brown, J. How, 2014, Histochemistry and Cell Biology.

Functional Correlates of Mutations in β-Catenin Exon 3 Phosphorylation Sites*

R. Gaynor, D. Rimm, Yumi Yamamoto, 2003, Journal of Biological Chemistry.

Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer.

S. Agarwal, K. Syrigos, D. Rimm, 2011, The American journal of pathology.

Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance

D. Rimm, M. Hurwitz, H. Kluger, 2022, Frontiers in Oncology.

Whole exome sequencing of pre-treatment biopsies from the neoALTTO trial to identify DNA aberrations associated with response to HER2-targeted therapies

C. Sotiriou, L. Pusztai, J. Baselga, 2015 .

Loss of p120ctn in human colorectal cancer predicts metastasis and poor survival.

D. Rimm, A. Reynolds, J. Gold, 1998, Cancer letters.

Making every cell like HeLa a giant step for cell culture.

S. Agarwal, D. Rimm, 2012, The American journal of pathology.

Tissue Microarray Analysis of β-Catenin in Colorectal Cancer Shows Nuclear Phospho-β-catenin Is Associated with a Better Prognosis

D. Rimm, G. Chung, L. Charette, 2001 .

Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade

M. Gerstein, K. Syrigos, D. Rimm, 2022, npj Precision Oncology.

Quantitative analysis of estrogen receptor heterogeneity in breast cancer

D. Rimm, R. Camp, G. Chung, 2007, Laboratory Investigation.

Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas

S. Ariyan, Hongyu Zhao, R. Halaban, 2004, Cancer Research.

Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma.

D. Rimm, B. G. Gould Rothberg, 2010, The Journal of investigative dermatology.

Marginal and joint distributions of S100, HMB-45, and Melan-A across a large series of cutaneous melanomas.

William R. Bradley, D. Rimm, K. Schalper, 2013, Archives of pathology & laboratory medicine.

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group

M. Ellis, S. Leung, T. Nielsen, 2020, Journal of the National Cancer Institute.

Of Membrane Stability and Mosaics: The Spectrin Cytoskeleton

D. Rimm, J. Sinard, J. Morrow, 2011 .

False-positive pathology: improving reproducibility with the next generation of pathologists

D. Rimm, R. Homer, Benjamin L. Mazer, 2019, Laboratory Investigation.

Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study

M. García-Closas, M. Sherman, L. Brinton, 2007, Cancer Epidemiology Biomarkers & Prevention.

Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions

D. Elder, R. Halaban, D. Rimm, 2008, Modern Pathology.

Activated Wnt/ß-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model

R. Moon, D. Rimm, A. Berger, 2009, Proceedings of the National Academy of Sciences.

β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas.

D. Rimm, M. Taketo, M. McMahon, 2011, Cancer cell.

Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.

M. Bracken, D. Rimm, B. G. Gould Rothberg, 2009, Journal of the National Cancer Institute.

Resolution of Acanthamoeba castellanii chromosomes by pulsed field gel electrophoresis and construction of the initial linkage map

David L. Rimm, Thomas D. Pollard, T. Pollard, 1988, Chromosoma.

Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy

Xu Zhou, R. Herbst, D. Rimm, 2019, Nature Medicine.

The cell adhesion molecule, E‐cadherin, distinguishes mesothelial cells from carcinoma cells in fluids

D. Rimm, T. D'Aquila, K. Schofield, 1997, Cancer.

E‐cadherin expression is a sensitive and specific method for detection of carcinoma cells in fluid specimens

D. Rimm, Kevin Schofield, Thomas D'Aquila, 2000, Diagnostic cytopathology.

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

Vamsidhar Velcheti, David L Rimm, Lajos Pusztai, 2014, Clinical Cancer Research.

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

S. Mallal, R. Yelensky, S. Loi, 2015, Clinical Cancer Research.

Expression of c‐met is a strong independent prognostic factor in breast carcinoma

E. Rimm, D. Rimm, E. Fearon, 1998, Cancer.

Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer

Sung-Bae Kim, C. Sotiriou, L. Pusztai, 2021, Clinical Cancer Research.

Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges.

D. Rimm, S. Hu-Lieskovan, J. Moser, 2020, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Structural analysis of the murine IgG3 constant region gene.

F. Blattner, D. Rimm, P. Tucker, 1984, The EMBO journal.

Identification of functional regions on the tail of Acanthamoeba myosin- II using recombinant fusion proteins. II. Assembly properties of tails with NH2- and COOH-terminal deletions

T. Pollard, D. Rimm, J. Sinard, 1990, The Journal of cell biology.

Quantitative assessment of miR34a as an independent prognostic marker in breast cancer

S. Agarwal, M. Sherman, D. Rimm, 2014, British Journal of Cancer.

microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma.

Yonghong Xiao, David L Rimm, James J Collins, 2012, Cancer discovery.

miR-34a as a novel regulator of TGFβ signaling in GBM

J. Collins, L. Chin, W. Wiedemeyer, 2012 .

Quantitative Image Analysis for Tissue Biomarker Use: A White Paper From the Digital Pathology Association

L. Pantanowitz, A. Parwani, D. Rimm, 2021, Applied immunohistochemistry & molecular morphology : AIMM.

Functional correlates of mutations in beta-catenin exon 3 phosphorylation sites.

R. Gaynor, D. Rimm, Yumi Yamamoto, 2003, The Journal of biological chemistry.

Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma.

D. Rimm, G. Tallini, G. García-Rostán, 1999, Cancer research.

Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer

Y. Kluger, D. Rimm, J. Giltnane, 2008, Breast Cancer Research.

Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma

Y. Kluger, D. Rimm, R. Camp, 2009, Clinical Cancer Research.

Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes

R. Herbst, D. Rimm, K. Politi, 2019, Clinical Cancer Research.

Localization and quantitation of expression of the cell motility-related protein thymosin beta15 in human breast tissue.

D. Rimm, B. Zetter, J. Gold, 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

I. Wistuba, F. Hirsch, D. Rimm, 2021, Nature Reviews Clinical Oncology.

PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis

Y. Kluger, R. Halaban, D. Rimm, 2014, Clinical Cancer Research.

Expression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast Cancer

Yuval Kluger, David L Rimm, Y. Kluger, 2008, Clinical Cancer Research.

Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case–control study

L. Pusztai, D. Rimm, K. Blenman, 2021, Breast Cancer Research.

Macrophage Colony-Stimulating Factor-1 Receptor Expression Is Associated with Poor Outcome in Breast Cancer by Large Cohort Tissue Microarray Analysis

D. Rimm, M. Dolled-Filhart, R. Camp, 2004, Clinical Cancer Research.

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial

C. Sotiriou, S. Loi, L. Pusztai, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer

S. Agarwal, D. Rimm, T. Rohan, 2012, Breast Cancer Research.

Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study

R. Schiff, P. Neven, J. Mackey, 2011, Clinical Cancer Research.

Characterization of alpha-actinin from Acanthamoeba.

T. Pollard, D. Bichell, D. Rimm, 1986, Cell motility and the cytoskeleton.

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence

R. Yelensky, H. Gómez, Jenny C. Chang, 2016, Science Translational Medicine.

Not Just Digital Pathology, Intelligent Digital Pathology.

David L Rimm, Balazs Acs, D. Rimm, 2018, JAMA oncology.

PKCε Promotes Oncogenic Functions of ATF2 in the Nucleus while Blocking Its Apoptotic Function at Mitochondria

T. Ideker, D. Rimm, H. Kluger, 2012, Cell.

Stathmin expression and its relationship to microtubule‐associated protein tau and outcome in breast cancer

L. Harris, D. Rimm, A. Molinaro, 2012, Cancer.

Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells.

D. Rimm, S. Kobayashi, K. Politi, 2016, Cell reports.

An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer

John M S Bartlett, Liron Pantanowitz, Carsten Denkert, 2018, Modern Pathology.

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up

I. Wistuba, S. Swisher, R. Herbst, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer

L. Pusztai, D. Rimm, K. Schalper, 2016, Breast Cancer Research.

Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error

M. Loda, M. Shipitsin, D. Rimm, 2014, British Journal of Cancer.

Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.

S. Mane, C. Larsson, D. Rimm, 2015, Human molecular genetics.

Clinically relevant shifts in endogenous and exogenous mutational processes proximate to metastasis support local consolidative treatment in EGFR-driven non-small cell lung cancer

J. Townsend, D. Rimm, J. Contessa, 2021, medRxiv.

Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade

Ludmila V. Danilova, A. Szalay, L. Cope, 2021, Science.

Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality

K. Syrigos, D. Rimm, H. Kluger, 2021, npj Precision Oncology.

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis.

David L Rimm, Ludmila V. Danilova, Clifford Hoyt, 2019, JAMA oncology.

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis

R. Herbst, K. Syrigos, D. Rimm, 2019, Clinical Cancer Research.

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)

R. Herbst, D. Rimm, S. Gettinger, 2019, Journal of Immunotherapy for Cancer.

Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.

S. Loi, J. Kim, J. Sosman, 2018, JCI insight.

Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations

K. Syrigos, D. Rimm, K. Schalper, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

R. Herbst, D. Zelterman, D. Rimm, 2018, Nature Communications.

Implications of the tumor immune microenvironment for staging and therapeutics

J. Taube, D. Rimm, J. Galon, 2018, Modern Pathology.

Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer

R. Herbst, D. Rimm, K. Schalper, 2016, Clinical Cancer Research.

PD‐L1 Expression in Lung Cancer

F. Hirsch, D. Rimm, Hui Yu, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Immunological differences between primary and metastatic breast cancer

L. Pusztai, D. Rimm, V. Bossuyt, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Correlates and Determinants of Nuclear Epidermal Growth Factor Receptor Content in an Oropharyngeal Cancer Tissue Microarray

D. Rimm, B. Egleston, A. Psyrri, 2008, Cancer Epidemiology Biomarkers & Prevention.

Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis

D. Rimm, R. Camp, A. Psyrri, 2005, Clinical Cancer Research.

Quantitative, fluorescence-based in-situ assessment of protein expression.

D. Rimm, J. Giltnane, C. Moeder, 2009, Methods in molecular biology.

Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer

M. Loda, P. Kantoff, F. Saad, 2015, Clinical Cancer Research.

Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality

M. Shipitsin, D. Rimm, P. Blume-Jensen, 2014, Proteome Science.

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo

Pei Hui, Jonathan Black, David L Rimm, 2016, British Journal of Cancer.

CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression

L. Pusztai, D. Rimm, V. Bossuyt, 2022, Science Translational Medicine.

CECR2 Drives Breast Cancer Metastasis by Suppressing Macrophage Inflammatory Responses

L. Pusztai, Ming-zhu Yin, D. Rimm, 2020, bioRxiv.

Controversies at the cytoplasmic face of the cadherin-based adhesion complex.

D. Rimm, E. Provost, 1999, Current opinion in cell biology.

α-Catenin Can Form Asymmetric Homodimeric Complexes and/or Heterodimeric Complexes with β-Catenin*

D. Rimm, P. Maupin, J. Morrow, 1997, The Journal of Biological Chemistry.

STING enhances cell death through regulation of reactive oxygen species and DNA damage

D. Rimm, J. Contessa, B. Burtness, 2021, Nature Communications.

as an independent prognostic marker in breast cancer

S. Agarwal, D. Rimm, T. Rohan, 2012 .

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

E. Perez, C. Sotiriou, S. Loi, 2021, NPJ breast cancer.

Tissue microarray‐based analysis shows phospho‐β‐catenin expression in malignant melanoma is associated with poor outcome

D. Rimm, R. Camp, Bradley L. Smith, 2003, International journal of cancer.

Proinvasion metastasis drivers in early-stage melanoma are oncogenes.

Gerald C. Chu, L. Chin, Yonghong Xiao, 2011, Cancer cell.

Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer.

Y. Kluger, D. Rimm, R. Camp, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization.

F. Slack, S. Agarwal, D. Rimm, 2012, BioTechniques.

Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma.

Annabelle L. Fonseca, S. Mane, C. Larsson, 2015, The Journal of clinical endocrinology and metabolism.

The Semaphorin 7A Receptor Plexin C1 Is Lost During Melanoma Metastasis

D. Rimm, G. Scott, R. Lazova, 2009, The American Journal of dermatopathology.

Prognostic Significance of p16 Protein Levels in Oropharyngeal Squamous Cell Cancer

D. Rimm, M. Harigopal, A. Psyrri, 2004, Clinical Cancer Research.

Prognostic Significance of p 16 Protein Levels in Oropharyngeal Squamous Cell Cancer

D. Rimm, M. Harigopal, A. Psyrri, 2004 .

Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis.

D. Rimm, R. Camp, M. Harigopal, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DNA Hypermethylation of ESR1 and PGR in Breast Cancer: Pathologic and Epidemiologic Associations

P. Laird, M. García-Closas, M. Sherman, 2009, Cancer Epidemiology, Biomarkers & Prevention.

Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib

K. Flaherty, J. Kirkwood, K. Nathanson, 2014, Clinical Cancer Research.

Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival.

R. Halaban, D. Rimm, H. Kluger, 2003, Cancer research.

Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma.

N. Sharpless, D. Rimm, C. Der, 2007, Cancer research.

Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction.

Victor G Prieto, Jeffrey E Gershenwald, David L Rimm, 2005, Cancer research.

C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas

D. Rimm, M. Sznol, R. Camp, 2009, Clinical Cancer Research.

Patient-derived conditionally reprogrammed cells maintain intra-tumor genetic heterogeneity

S. Agarwal, D. Rimm, L. O. Penalva, 2018, Scientific Reports.

Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer.

D. Rimm, J. Giltnane, K. Jirström, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma

P. Oettgen, D. Rimm, A. Mercurio, 2006, Oncogene.

BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort

M. Prados, W. Curran, J. Knisely, 2021, Oncology.

Molecular classification of nonsmall cell lung cancer using a 4‐protein quantitative assay

Taxiarchis Botsis, David L Rimm, Dimitrios Dougenis, 2012, Cancer.

Purification and characterization of an Acanthamoeba nuclear actin- binding protein

T. Pollard, D. Rimm, 1989, The Journal of cell biology.

Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease.

Y. Kluger, D. Rimm, R. Camp, 2005, Cancer research.

Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance

D. Rimm, K. Schalper, A. Santin, 2017, Gynecologic oncology.

Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response

Y. Reshetnyak, P. Glazer, D. Rimm, 2019, The Journal of clinical investigation.

Direct Interaction of the C-Terminal Domain of α-Catenin and F-Actin is Necessary for Stabilized Cell-Cell Adhesion

David L Rimm, Derek J Pappas, D. Rimm, 2006, Cell communication & adhesion.

PECAM-1 (CD31) functions as a reservoir for and a modulator of tyrosine-phosphorylated beta-catenin.

D. Rimm, S. Mahooti, N. Ilan, 1999, Journal of cell science.

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer

J. Taube, I. Wistuba, F. Hirsch, 2017, JAMA oncology.

A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1

D. Rimm, Jamaal A Rehman, V. Neumeister, 2017, JAMA oncology.

High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas

Vamsidhar Velcheti, David L. Rimm, Kurt Schalper, 2013, PloS one.

Pin1 modulates ERα levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation

D. Rimm, K. Schalper, K. Lu, 2014, Oncogene.

High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma

G. Bepler, L. Tanoue, D. Boffa, 2009, Clinical Cancer Research.

High Expression of MammalianTarget of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma

G. Bepler, D. Boffa, K. Syrigos, 2009 .

Acquired resistance to HER2-targeted therapies creates vulnerability to ATP synthase inhibition.

D. Rimm, Zongzhi Z. Liu, D. Stern, 2019, Cancer research.

Cruella: developing a scalable tissue microarray data management system.

David L Rimm, James D Cowan, David P Tuck, 2006, Archives of pathology & laboratory medicine.

An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer

J. Hartman, D. Rimm, A. Ehinger, 2021, Clinical Cancer Research.

Novel tyramide‐based tyrosinase assay for the detection of melanoma cells in cytological preparations

R. Halaban, D. Rimm, C. Angeletti, 2004, Diagnostic cytopathology.

Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer Cells

Valsamo Anagnostou, Robert Camp, G. Bepler, 2012, PloS one.

Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer

L. Pusztai, D. Rimm, A. Bellizzi, 2020, Modern Pathology.

The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice

A. Gown, T. Nielsen, E. Thompson, 2020, The Journal of pathology.

“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy

Chao Li, Gang Han, Marius Ilie, 2019, Modern Pathology.

Quantitative Assessment of PD-L1 as an Analyte in Immunohistochemistry Diagnostic Assays using a Standardized Cell Line Tissue Microarray

A. Gown, M. Mino‐Kenudson, D. Rimm, 2019, Laboratory Investigation.

Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer

J. Taube, L. Pusztai, I. Wistuba, 2019, Breast Cancer Research.

Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma

D. Rimm, V. Pelekanou, Jamaal A Rehman, 2017, Journal of Immunotherapy for Cancer.

Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study.

David L Rimm, Michael Reiss, M. Reiss, 2002, Cancer research.

Associated with Poor Outcome : A Tissue Microarray Study Alterations of Smad Signaling in Human Breast Carcinoma Are Updated

M. Reiss, D. Rimm, R. Camp, 2002 .

Quantitative and Pathologist-Read comparison of the Heterogeneity of Programmed Death-Ligand 1(PD-L1) expression in Non-Small Cell Lung Cancer

D. Rimm, Gang Han, K. Schalper, 2016, Modern Pathology.

ORAL01.01: A Prospective, Multi‐Institutional Assessment of Four Assays for PD‐L1 Expression in NSCLC by Immunohistochemistry: Topic: Pathology

J. Taube, I. Wistuba, F. Hirsch, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR‐GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma

K. Syrigos, D. Rimm, K. Schalper, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells

S. Agarwal, L. Harris, D. Rimm, 2009, British Journal of Cancer.

Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)

D. Rimm, K. Schalper, V. Velcheti, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The function, proteolytic processing, and histopathology of Met in cancer.

S. Agarwal, J. Bordeaux, D. Rimm, 2009, Advances in cancer research.

Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma

E. Rimm, D. Rimm, R. Camp, 1999, Cancer.

Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non–Small Cell Lung Cancer

D. Rimm, K. Schalper, K. Syrigos, 2021, Clinical Cancer Research.

Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry

D. Rimm, K. Schalper, V. Pelekanou, 2021, Clinical Cancer Research.

Type of Melanoma Mitogen-Activated Protein Kinase Signaling Shows a New Lack of Extracellular Signal-Regulated Kinase

N. Sharpless, D. Rimm, C. Der, 2007 .

Molecular biology in cytopathology

D. Rimm, 2000, Cancer.

High Frequency of Putative Ovarian Cancer Stem Cells With CD44/CK19 Coexpression Is Associated With Decreased Progression-Free Intervals In Patients With Recurrent Epithelial Ovarian Cancer

D. Rimm, G. Mor, D. Silasi, 2013, Reproductive Sciences.

Subcellular Localization and Protein Levels of Cyclin-Dependent Kinase Inhibitor p 27 Independently Predict for Survival in Epithelial Ovarian Cancer

D. Rimm, R. Camp, A. Psyrri, 2005 .

High level PHGDH expression in breast is predominantly associated with keratin 5‐positive cell lineage independently of malignancy

D. Rimm, I. Gromova, P. Gromov, 2015, Molecular oncology.

Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort

D. Rimm, J. Giltnane, R. Camp, 2009, Cancer.

Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality

David L Rimm, Eldar Giladi, M. Shipitsin, 2014, Proteome Science.

Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology.

P. Lambin, D. Lacombe, P. Span, 2019, European journal of cancer.

Location of the head-tail junction of myosin

T. Pollard, D. Rimm, J. Sinard, 1989, The Journal of cell biology.

Subcellular Localization and Protein Levels of Cyclin-Dependent Kinase Inhibitor p27 Independently Predict for Survival in Epithelial Ovarian Cancer

M. Dimopoulos, D. Rimm, R. Camp, 2005, Clinical Cancer Research.

Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death

Jing Wang, Prathamesh M. Kulkarni, David L. Rimm, 2019, Clinical Cancer Research.

Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study

Anagha P. Jadhav, A. Gown, M. Ellis, 2022, Modern Pathology.

Ki67 reproducibility using digital image analysis: an inter-platform and inter-operator study

David L Rimm, Yalai Bai, Maria Toki, 2018, Laboratory Investigation.

Tissue microarrays: leaping the gap between research and clinical adoption.

D. Rimm, M. Dolled-Filhart, M. Gustavson, 2013, Personalized medicine.

Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.

Baljit Singh, D. Rimm, M. Dolled-Filhart, 2003, Cancer research.

Automated quantitative analysis of DCC tumor suppressor protein in ovarian cancer tissue microarray shows association with beta-catenin levels and outcome in patients with epithelial ovarian cancer.

M. Dimopoulos, D. Rimm, R. Camp, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Vinculin Is Associated with the E-cadherin Adhesion Complex*

D. Rimm, R. Hazan, P. Borgen, 1997, The Journal of Biological Chemistry.

High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology

L. Tanoue, D. Boffa, K. Syrigos, 2010, BMC Cancer.

Markers of Epithelial to Mesenchymal Transition in Association with Survival in Head and Neck Squamous Cell Carcinoma (HNSCC)

D. Rimm, A. Psyrri, G. Fountzilas, 2014, PloS one.

miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer.

Christopher J. Cheng, F. Slack, L. Pusztai, 2016, Cancer research.

Objective measurement and clinical significance of TILs in non-small cell lung cancer.

R. Herbst, K. Syrigos, D. Rimm, 2015, Journal of the National Cancer Institute.

Quantitative Assessment Shows Loss of Antigenic Epitopes as a Function of Pre-analytic Variables

D. Rimm, R. Camp, A. Molinaro, 2011, Laboratory Investigation.

Long-term preservation of antigenicity on tissue microarrays

D. Rimm, R. Camp, L. Charette, 2004, Laboratory Investigation.

A proposal for validation of antibodies

Emma Lundberg, Mathias Uhlen, Henry Rodriguez, 2016, Nature Methods.

Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study

J. Bergh, J. Hartman, D. Rimm, 2021, npj Breast Cancer.

Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study

J. Bergh, J. Hartman, D. Rimm, 2021, NPJ breast cancer.

The Pathologists' Conundrum.

S. Schnitt, D. Rimm, S. Dacic, 2022, Archives of pathology & laboratory medicine.

Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit.

J. Taube, M. Oberley, R. Herbst, 2022, JCO precision oncology.

Determination of the number of observers needed to evaluate a subjective test and its application in two PD‐L1 studies

D. Rimm, M. Schell, Emily S. Reisenbichler, 2021, Statistics in medicine.

Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study

J. Taube, I. Wistuba, D. Rimm, 2021, Journal for ImmunoTherapy of Cancer.

PD-L1 Expression Scoring: Non-Interchangeable, Non-Interpretable, Neither, or Both.

D. Rimm, S. Shafi, N. Gavrielatou, 2021, Journal of the National Cancer Institute.

Putting the Microenvironment into the Immunotherapy Companion Diagnostic

D. Rimm, M. Moutafi, 2021, Clinical Cancer Research.

OP-JNCI210108 1613..1614

D. Rimm, S. Shafi, N. Gavrielatou, 2021 .

PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer

L. Pusztai, D. Rimm, K. Blenman, 2020, Clinical Cancer Research.

Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry

Kelly P. Stanton, Ruth R. Montgomery, Y. Kluger, 2019, Clinical Cancer Research.

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma

J. Witte, T. Ho, J. Kim, 2018, Clinical Cancer Research.

Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial

G. Hortobagyi, L. Pusztai, P. Porter, 2018, Molecular Cancer Therapeutics.

Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance

L. Pusztai, D. Rimm, V. Pelekanou, 2017, Breast Cancer Research.

A prospective, multi-institutional diagnostic trial to determine pathologist accuracy in estimation of percentage of malignant cells.

David L Rimm, Meera Hameed, Patricia Vasalos, 2013, Archives of pathology & laboratory medicine.

Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes

G. A. Stringer, Amy R. Peck, H. Rui, 2012, Breast Cancer Research.

Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement

D. Rimm, E. Ratner, P. Schwartz, 2018, Clinical Cancer Research.

Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistry

D. Rimm, Summar F. Siddiqui, 2010, Breast Cancer Research.

Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy

R. Herbst, D. Rimm, S. Gettinger, 2019, Clinical Cancer Research.

Quantitative Analysis of Estrogen Receptor Expression Shows SP1 Antibody Is More Sensitive Than 1D5

D. Rimm, M. Harigopal, M. Prasad, 2012, Applied immunohistochemistry & molecular morphology : AIMM.

Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer

L. Harris, P. Glazer, D. Rimm, 2012, Breast Cancer Research and Treatment.

Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome.

David L Rimm, Marisa Dolled-Filhart, D. Rimm, 2006, Cancer research.

αB‐crystallin as a marker of lymph node involvement in breast carcinoma

D. Rimm, H. Kluger, A. Berger, 2004, Cancer.

Construction and analysis of multiparameter prognostic models for melanoma outcome.

D. Rimm, B. G. Rothberg, 2014, Methods in molecular biology.

Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies.

Jeffrey W. Smith, G. Mills, Y. Kluger, 2015, Cancer cell.

Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes

G. A. Stringer, Adam Ertel, Terry Hyslop, 2012, Breast Cancer Research.

Identification of functional regions on the tail of Acanthamoeba myosin- II using recombinant fusion proteins. I. High resolution epitope mapping and characterization of monoclonal antibody binding sites

T. Pollard, D. Rimm, D. Kaiser, 1990, The Journal of cell biology.

Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer

D. Rimm, B. Ács, V. Bossuyt, 2019, npj Breast Cancer.

High Concordance of a Closed-System, RT-qPCR Breast Cancer Assay for HER2 mRNA, Compared to Clinically Determined Immunohistochemistry, Fluorescence in situ Hybridization, and Quantitative Immunofluorescence

D. Rimm, V. Neumeister, V. Chu, 2017, Laboratory investigation; a journal of technical methods and pathology.

Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer

D. Rimm, K. Schalper, V. Velcheti, 2017, Journal of Immunotherapy for Cancer.

Construction of coliphage lambda Charon vectors with BamHI cloning sites.

F. Blattner, J. Kucera, D. Rimm, 1980, Gene.

Prognostic Significance of Cadherin-Based Adhesion Molecules in Cutaneous Malignant Melanoma

D. Rimm, A. Berger, B. G. Gould Rothberg, 2008, Cancer Epidemiology Biomarkers & Prevention.

GOLPH3 modulates mTOR signaling and rapamycin sensitivity in cancer

Yonghong Xiao, Lynda Chin, Valsamo Anagnostou, 2009, Nature.

Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303).

D. Rimm, S. Spencer, H. Wanebo, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer

Dafydd G. Thomas, D. Rimm, K. Schalper, 2018, npj Breast Cancer.

Molecular Analysis of Non–Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition

Adrian V. Lee, S. McDonald, D. Rimm, 2010, Clinical Cancer Research.

Loss of Smad Signaling in Human Colorectal Cancer Is Associated with Advanced Disease and Poor Prognosis

Weichung J Shih, Yong Lin, David L Rimm, 2003, Cancer journal.

Automated Objective Determination of Percentage of Malignant Nuclei for Mutation Testing

Kisha Mitchell, D. Rimm, K. Schalper, 2014, Applied immunohistochemistry & molecular morphology : AIMM.

Defining Molecular Phenotypes of Human Papillomavirus–Associated Oropharyngeal Squamous Cell Carcinoma

D. Rimm, R. Camp, A. Psyrri, 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma

D. Zelterman, D. Rimm, H. Kluger, 2019, Journal of Immunotherapy for Cancer.

Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma

Daniel Zelterman, David L. Rimm, Balazs Acs, 2019, Clinical Cancer Research.

JAKs and STATs as Biomarkers of Disease

D. Rimm, M. Dolled-Filhart, 2003 .

PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer

L. Pusztai, D. Rimm, V. Bossuyt, 2014, Cancer Immunology Research.

Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer

D. Rimm, V. Bossuyt, Jason R. Brown, 2014, Clinical Cancer Research.

Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer

David L Rimm, M. Dimopoulos, D. Rimm, 2005, Clinical Cancer Research.

Gab2-mediated signaling promotes melanoma metastasis.

D. Rimm, N. Nowak, S. Gruvberger-Saal, 2009, The American journal of pathology.

Gene expression array analysis to determine tissue of origin of carcinoma of unknown primary

D. Rimm, M. Dolled-Filhart, 2013, Cancer cytopathology.

Truncated DCC Reduces N-Cadherin/Catenin Expression and Calcium-Dependent Cell Adhesion in Neuroblastoma Cells

J. Meyerhardt, D. Rimm, M. Reyes-Múgica, 2001, Laboratory Investigation.

Receptor protein tyrosine phosphatase PTPmu associates with cadherins and catenins in vivo

D. Rimm, S. Brady-Kalnay, N. Tonks, 1995, The Journal of cell biology.

Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene.

D. Rimm, A. Arnold, J. Wysolmerski, 2006, The Journal of clinical endocrinology and metabolism.

Molecular markers for prognosis after isolated postmastectomy chest wall recurrence

D. Rimm, B. Haffty, D. Carter, 2004, Cancer.

Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel

K. Flaherty, J. Kirkwood, K. Nathanson, 2013, PloS one.

α-Catenin Binds Directly to Spectrin and Facilitates Spectrin-Membrane Assembly in Vivo *

D L Rimm, D. Rimm, J. Morrow, 2001, The Journal of Biological Chemistry.

Novel inactivating mutations of transforming growth factor‐β type I receptor gene in head‐and‐neck cancer metastases

M. Reiss, D. Rimm, J. McNiff, 2001, International journal of cancer.

Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers

L. Pusztai, T. Qing, D. Rimm, 2020, JCO precision oncology.

Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models

Yuval Kluger, David L Rimm, Fabio Parisi, 2010, Breast Cancer Research.

Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing

Annette S. Kim, Neal I. Lindeman, David L. Rimm, 2017, JAMA oncology.

Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches

H. Putter, D. Rea, D. Rimm, 2012 .

Quantitative Assessment of Tissue Biomarkers and Construction of a Model to Predict Outcome in Breast Cancer Using Multiple Imputation

John W. Emerson, David L. Rimm, Marisa Dolled-Filhart, 2008, Cancer informatics.

Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib

K. Flaherty, K. Nathanson, D. Rimm, 2009, Clinical Cancer Research.

How current assay approval policies are leading to unintended imprecision medicine.

T. Nielsen, D. Rimm, C. Quinn, 2020, The Lancet. Oncology.

Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker

Yi Zhang, Jackie Szymonifka, Dennis C. Sgroi, 2013, Journal of the National Cancer Institute.

Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues.

D. Berry, F. Waldman, T. Nielsen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome Based Screening for Prognostic Phospho-RTK (Receptor Tyrosine Kinase) Antibodies Using Tissue Microarrays

D. Rimm, 2004 .

Tissue microarray‐based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors

D. Rimm, M. Dolled-Filhart, R. Camp, 2003, Cancer.

HSP90 as a marker of progression in melanoma.

Y. Kluger, D. Rimm, R. Camp, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer.

D. Rimm, R. Camp, G. Chung, 2008, Human Pathology.

Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.

K. Flaherty, D. Rimm, R. Camp, 2010, Human pathology.

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.

C. Sotiriou, C. Desmedt, D. Larsimont, 2013, Future oncology.

Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts

L. Harris, D. Rimm, R. Camp, 2011, Breast Cancer Research.

Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma

A. Scorilas, D. Rimm, V. Velcheti, 2015, Clinical Cancer Research.

Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer

Robert Camp, Brian L. Egleston, Bruce Haffty, 2007, Cancer Epidemiology Biomarkers & Prevention.

Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites

D. Rimm, M. Sznol, Lieping Chen, 2015, Clinical Cancer Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma

K. Flaherty, J. Kirkwood, K. Nathanson, 2015, Clinical Cancer Research.

Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma

Rajarsi R. Gupta, R. Vanguri, D. Rimm, 2021, Scientific Reports.

Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma

Rajarsi R. Gupta, J. Saltz, R. Vanguri, 2021, Scientific reports.

Automated Quantitative Analysis of E-Cadherin Expression in Lymph Node Metastases Is Predictive of Survival in Invasive Ductal Breast Cancer

David L Rimm, D. Rimm, R. Camp, 2005, Clinical Cancer Research.

Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma.

David L Rimm, John Joe, D. Rimm, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Diagnosis of “ASCUS” in women over age 50 is less likely to be associated with dysplasia

D. Rimm, K. Flynn, 2001, Diagnostic cytopathology.

Atypical squamous cells of undetermined significance: Correlative histologic and follow‐up studies from an academic medical center

W. Frable, D. Rimm, M. Pedigo, 1997, Diagnostic cytopathology.

Comparison of HER2 and Phospho-HER2 Expression between Biopsy and Resected Breast Cancer Specimens Using a Quantitative Assessment Method

J. Bordeaux, D. Rimm, D. Stern, 2013, PloS one.

A possible association of human papilloma virus with a subset of colorectal adenocarcinomas

D. Rimm, R. Camp, G. Chung, 2004 .

Computational Imaging, and Statistical Analysis of Tissue Microarrays: Quantitative Automated Analysis of Tissue Microarrays

D. Rimm, R. Camp, A. Berger, 2006 .

Subjective differences in outcome are seen as a function of the immunohistochemical method used on a colorectal cancer tissue microarray.

David L Rimm, D. Rimm, G. Chung, 2002, Clinical colorectal cancer.

Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study.

M. García-Closas, M. Sherman, L. Brinton, 2007, Cancer research.

Loss of antigenicity with tissue age in breast cancer

M. Nerenberg, D. Rimm, Gang Han, 2016, Laboratory Investigation.

Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure.

G. A. Stringer, Amy R. Peck, M. Nevalainen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Her2/neu is not a commonly expressed therapeutic target in melanoma – a large cohort tissue microarray study

S. Ariyan, R. Halaban, D. Rimm, 2004, Melanoma research.

OP-JNCI200205 808..819

M. Ellis, S. Leung, T. Nielsen, 2021 .

ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC

D. Rimm, G. Mcmahon, V. Neumeister, 2017, PloS one.

High-Plex Predictive Marker Discovery for Melanoma Immunotherapy–Treated Patients Using Digital Spatial Profiling

K. Syrigos, D. Rimm, S. Warren, 2019, Clinical Cancer Research.

CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers

L. Pusztai, D. Rimm, K. Schalper, 2018, Breast Cancer Research.

Transcriptional defects underlie loss of E-cadherin expression in breast cancer.

A. Woodard, D. Rimm, E. Fearon, 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer

D. Rimm, M. Sznol, R. Camp, 2005, Clinical Cancer Research.

Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time

Y. Kluger, D. Rimm, V. Anagnostou, 2015, Laboratory Investigation.

Significance of PD-L1, IDO-1, and B7-H4 expression in lung cancer.

R. Herbst, K. Syrigos, D. Rimm, 2015 .

Abstract LB-318: Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE study): Reproducibility assessment of an automated multiplexed immunofluorescence slide staining, imaging, and analysis workflow

Mei Jiang, Janis M. Taube, Yi Zheng, 2019, Tumor Biology.

Proof of the Quantitative Potential of Immunofluorescence by Mass Spectrometry

K. Syrigos, D. Rimm, T. Hembrough, 2016, Laboratory Investigation.

Analytic Variability in Immunohistochemistry Biomarker Studies

K. Syrigos, D. Rimm, J. Giltnane, 2010, Cancer Epidemiology, Biomarkers & Prevention.

Expression of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptors 1 and 2 in Melanoma

K. Flaherty, R. Halaban, D. Rimm, 2006, Clinical Cancer Research.

Imaging , Diagnosis , Prognosis In Situ Tumor PD-L 1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

L. Pusztai, D. Rimm, K. Schalper, 2014 .

Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues.

Yuval Kluger, David L Rimm, Valsamo Anagnostou, 2012, Journal of the National Cancer Institute.

Quantitative In Situ Measurement of Estrogen Receptor mRNA Predicts Response to Tamoxifen

Xiao-Jun Ma, Yuling Luo, J. Bordeaux, 2012, PloS one.

Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model

D. Rimm, R. Camp, M. Cregger, 2007, Laboratory Investigation.

Benign lymph node microenvironment is associated with response to immunotherapy

D. Rimm, Deepika Kumar, Mina L. Xu, 2020, Precision clinical medicine.

Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer

D. Rimm, J. Zugazagoitia, Kyla E. Driscoll, 2021, Cancers.

Assessment of PI3 kinase as a druggable target in melanoma

K. Flaherty, D. Rimm, R. Camp, 2007 .

The effect of BCG intravesical therapy and recurrence on PDL1 expression in non-invasive bladder cancers.

D. Rimm, M. Hurwitz, K. Schalper, 2015 .

Parathyroid hormone-related protein maintains mammary epithelial fate and triggers nipple skin differentiation during embryonic breast development.

D. Rimm, J. Foley, J. Wysolmerski, 2001, Development.

Tumorigenesis and Neoplastic Progression Gab 2-Mediated Signaling Promotes Melanoma Metastasis

D. Rimm, N. Nowak, S. Gruvberger-Saal, 2010 .

PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors

Yuval Kluger, David L Rimm, Gabriela Turcu, 2017, Clinical Cancer Research.

Worldwide Frequency of Commonly Detected EGFR Mutations.

D. Rimm, N. Lindeman, R. Graham, 2017, Archives of pathology & laboratory medicine.

Microvessel area using automated image analysis is reproducible and is associated with prognosis in breast cancer.

D. Rimm, R. Camp, G. Chung, 2009, Human pathology.

In Situ Measurement of miR-205 in Malignant Melanoma Tissue Supports its Role as a Tumor Suppressor MicroRNA

S. Agarwal, D. Rimm, Lewis D. Hahn, 2012, Laboratory Investigation.

Glucose and inflammation control islet vascular density and beta-cell function in NOD mice: control of islet vasculature and vascular endothelial growth factor by glucose.

D. Rimm, J. Kushner, K. Herold, 2011, Diabetes.

Melanoma Tissue Microarray (TMA) Cohort and Data Repository

D. Rimm, 2010 .

Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma

D. Rimm, H. Kluger, M. Bates, 2019, Journal of Immunotherapy for Cancer.

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab

David L Rimm, Natalie Sinclair, Yalai Bai, 2014, BMC Cancer.

Fine‐needle aspiration of follicular adenoma versus parathyroid adenoma

David L Rimm, Richard M Levenson, Kirk Gossage, 2007, Cancer.

Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303

D. Rimm, H. Wanebo, E. Kosmidis, 2014, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC : Eastern Cooperative Oncology Group E 2303

D. Rimm, H. Wanebo, E. Kosmidis, 2014 .

Calcium Sensor, NCS-1, Promotes Tumor Aggressiveness and Predicts Patient Survival

D. Rimm, Barbara E. Ehrlich, Lauren M. Moore, 2017, Molecular Cancer Research.

Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.

L. Pusztai, D. Rimm, Emily S. Reisenbichler, 2022, JAMA oncology.

Vascular endothelial growth factor, FLT‐1, and FLK‐1 analysis in a pancreatic cancer tissue microarray

D. Rimm, R. Camp, G. Chung, 2006, Cancer.

Structure-Function Studies of the Actin Filament System of Acanthamoeba

T. Pollard, D. Rimm, D. Kaiser, 1989 .

EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial

E. Perez, D. Rimm, J. Gralow, 2014, British Journal of Cancer.

Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer

Jeffrey H. Chuang, D. Rimm, Emily S. Reisenbichler, 2021, Modern Pathology.

In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients

Taiwo A. Togun, U. Dafni, J. Bordeaux, 2014, PloS one.

Short Communication Frequent Nuclear/Cytoplasmic Localization of b-Catenin without Exon 3 Mutations in Malignant Melanoma

D. Rimm, E. Fearon, K. Caca, 1999 .

Advances in Brief Frequent Mutation and Nuclear Localization of b-Catenin in Anaplastic Thyroid Carcinoma 1

D. Rimm, G. Tallini, G. García-Rostán, 1999 .

Dynamic Interaction of PTPμ with Multiple Cadherins In Vivo

D. Rimm, S. Brady-Kalnay, M. Kinch, 1998, The Journal of cell biology.

b- and g-Catenin Mutations, but not E-Cadherin Inactivation, Underlie T-Cell Factor/Lymphoid Enhancer Factor Transcriptional Deregulation in Gastric and Pancreatic Cancer

D. Rimm, E. Fearon, A. Yahanda, 1999 .

Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy

D. Rimm, H. Kluger, J. Zugazagoitia, 2020, Oncoimmunology.

Quantitative assessment of CMTM6 in the tumor microenvironment and association with response to PD-1 pathway blockade in advanced-stage non-small-cell lung cancer.

R. Herbst, D. Rimm, S. Gettinger, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study

A. Madabhushi, Xiangxue Wang, Jun Xu, 2020, The Lancet. Digital health.

‘Locked‐in syndrome’ for 27 years following a viral illness

P. Williamson, D. Rimm, V. Thadani, 1991, Neurology.

Differential expression of arrestins is a predictor of breast cancer progression and survival

Amy R. Peck, H. Rui, D. Rimm, 2011, Breast Cancer Research and Treatment.

Tissue microarray: a new technology for amplification of tissue resources.

D L Rimm, R L Camp, L A Charette, 2001, Cancer journal.

Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma

L. Harris, D. Rimm, A. Molinaro, 2011, Breast Cancer Research.

Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning.

K-R Müller, S Michiels, F Klauschen, 2018, Seminars in cancer biology.

Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.

L. Pusztai, D. Rimm, K. Schalper, 2015, Journal of the National Cancer Institute.

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

C. Sotiriou, S. Loi, L. Pusztai, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer.

K. Gelmon, D. Rimm, J. Giltnane, 2008, Archives of pathology & laboratory medicine.

Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers.

R. Herbst, D. Rimm, S. Gettinger, 2017 .

Targeting the CSF1/CSF1R Axis is a Potential Treatment Strategy for Malignant Meningiomas.

Mark W. Youngblood, D. Rimm, Lieping Chen, 2021, Neuro-oncology.

Automated Quantitative Analysis of Tissue Microarrays Reveals an Association between High Bcl-2 Expression and Improved Outcome in Melanoma

David L Rimm, Marisa Dolled-Filhart, D. Rimm, 2004, Cancer Research.

VEGF, VEGFR1, and VEGFR2 expression in melanoma

K. Flaherty, D. Rimm, M. Sznol, 2007 .

B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes

R. Herbst, K. Syrigos, D. Rimm, 2017, Clinical Cancer Research.

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

Andrew H. Beck, Clare C. Yu, M. N. Vidya, 2021, npj Breast Cancer.

Nuclear Localization of Signal Transducer and Activator of Transcription 3 in Head and Neck Squamous Cell Carcinoma Is Associated with a Better Prognosis

U. Dafni, A. Egloff, J. Grandis, 2010, Clinical Cancer Research.

Delay to formalin fixation ‘cold ischemia time’: effect on ERBB2 detection by in-situ hybridization and immunohistochemistry

David L Rimm, Raymond R Tubbs, Erinn Downs-Kelly, 2013, Modern Pathology.

PKC ε regulates ATF 2 availability to alter mitochondrial permeability following genotoxic stress

T. Ideker, D. Rimm, H. Kluger, 2013 .

Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: A population‐based analysis

M. García-Closas, N. Chatterjee, M. Sherman, 2007, International journal of cancer.

Automated measurement of estrogen receptor in breast cancer: a comparison of fluorescent and chromogenic methods of measurement

D. Rimm, K. Schalper, Daniel Carvajal, 2016, Laboratory Investigation.

Association between low estrogen receptor positive breast cancer and staining performance

D. Rimm, Emily S. Reisenbichler, Dennis Caruana, 2020, npj Breast Cancer.

Breast Cancer Misclassification: A Major Obstacle to Treatment?

D. Rimm, M. Gustavson, E. Romeo, 2011, Women's health.

PMCA2 regulates apoptosis during mammary gland involution and predicts outcome in breast cancer

D. Rimm, R. Camp, G. Chung, 2010, Proceedings of the National Academy of Sciences.

Quantitative Analysis of Breast Cancer Tissue Microarrays Shows High Cox-2 Expression Is Associated with Poor Outcome

David L Rimm, D. Rimm, R. Camp, 2007, Cancer investigation.

Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker

M. Erlander, D. Sgroi, P. Porter, 2013, Journal of the National Cancer Institute.

Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma.

G. Bepler, K. Syrigos, D. Rimm, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

S. Mallal, R. Yelensky, S. Loi, 2019, Clinical Cancer Research.

Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.

G. Hortobagyi, C. Shapiro, P. Porter, 2010, The American journal of pathology.

Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes

D. Rimm, J. Rinehart, Brandon M. Gassaway, 2021, Cancer Research.

Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer.

D. Rimm, S. Michiels, F. André, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer

Christos Hatzis, Lajos Pusztai, Kurt A. Schalper, 2016, Breast Cancer Research.

Abstract 3151: Quantitative measurement of Siglec-15 expression in non-small cell lung cancer and its association with PD-L1, B7-H4 and tumor infiltrating lymphocytes

R. Herbst, K. Syrigos, D. Rimm, 2019, Clinical Research (Excluding Clinical Trials).

Automated analysis of tissue microarrays.

D. Rimm, M. Dolled-Filhart, R. Camp, 2010, Methods in molecular biology.

Evaluation of the Prognostic Value of Cellular Inhibitor of Apoptosis Protein in Epithelial Ovarian Cancer Using Automated Quantitative Protein Analysis

M. Dimopoulos, D. Rimm, R. Camp, 2006, Cancer Epidemiology Biomarkers & Prevention.

Impact of microarray technologies on cytopathology. Overview of technologies and commentary on current and future implications for pathologists and cytopathologists.

D. Rimm, 2001, Acta Cytologica.

Phosphorylation of Akt ( Ser 473 ) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer

D. Rimm, R. Camp, B. Egleston, 2007 .

Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patientswith Epithelial Ovarian Cancer

D. Rimm, R. Camp, A. Psyrri, 2005 .

Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer

L. Pusztai, T. Qing, D. Rimm, 2022, npj Breast Cancer.

Spatial characterization and quantification of CD40 expression across cancer types

D. Rimm, A. Psyrri, F. Ahmed, 2023, BMC Cancer.

Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer.

W. Chen, D. Rimm, Zhaohai Yang, 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry.

D. Rimm, Emily S. Reisenbichler, J. Brock, 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Measurement of aldehyde dehydrogenase 1 expression defines a group with better prognosis in patients with non-small cell lung cancer.

S. Agarwal, K. Syrigos, D. Rimm, 2012, The American journal of pathology.

Ki67 as a Companion Diagnostic: Good or Bad News?

T. Nielsen, M. Dowsett, D. Rimm, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

with Poor Outcome Breast Cancer Shows Decreased Expression Is Associated-Catenin Expression in β Analysis of In situ Quantitative

D. Rimm, M. Dolled-Filhart, J. Giltnane, 2006 .

Quantitative, Spatially Defined Expression of Leukocyte-associated Immunoglobulin-like Receptor in Non–small Cell Lung Cancer

D. Rimm, S. Langermann, D. Flies, 2023, Cancer research communications.

An independent assessment of an artificial intelligence system for prostate cancer detection shows strong diagnostic accuracy

D. Rimm, D. Klimstra, J. Sinard, 2021, Modern Pathology.

A Tissue Quality Index – an Intrinsic Control for Measurement of Effects of Pre-analytical Variables on FFPE Tissue

Yuval Kluger, Valsamo Anagnostou, David L. Rimm, 2014, Laboratory Investigation.

Expertise vs evidence in assessment of breast biopsies: an atypical science.

D. Rimm, N. Davidson, 2015, JAMA.

ERβ splice variant expression in four large cohorts of human breast cancer patient tumors

L. Murphy, M. Sherman, D. Rimm, 2014, Breast Cancer Research and Treatment.

Abstract 2277: Loss of nuclear localized and tyrosine phosphorylated Stat5: A predictor of poor clinical outcome and increased risk of antiestrogen therapy failure in breast cancer

G. A. Stringer, M. Nevalainen, H. Rui, 2011 .

Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome

D. Rimm, V. Anagnostou, R. Camp, 2009, Breast Cancer Research and Treatment.

The ERα coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium

D. Rimm, J. Giltnane, Beatrice A. Howard, 2010, Molecular Cancer.

Multiplex Immunohistochemistry and Immunofluorescence: A Practical Update for Pathologists.

L. Pantanowitz, J. Taube, Dafydd G. Thomas, 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Abstract 3638: Quantitative assessment of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma

D. Rimm, K. Blenman, H. Kluger, 2018, Clinical Research (Excluding Clinical Trials).

The Effect of Black Cohosh on Ki67 expression and Tumor Volume: A Pilot Study of Ductal Carcinoma in Situ Patients

D. Rimm, M. Raghu, A. Chagpar, 2022, Integrative Cancer Therapies.

First Tissue-Agnostic Drug Approval Issued.

J. Wolchok, D. Rimm, S. Topalian, 2017, Cancer discovery.

PD-L 1 Expression Correlates with Tumor-In fi ltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer

L. Pusztai, D. Rimm, V. Bossuyt, 2015 .

Diagnostic classification of urothelial cells in urine cytology specimens using exclusively spectral information

David L Rimm, Richard Levenson, R. Levenson, 2004, Cancer.

Spatially Resolved and Quantitative Analysis of the Immunological Landscape in Human Meningiomas.

D. Rimm, Lieping Chen, M. Gunel, 2021, Journal of neuropathology and experimental neurology.

Autoantibodies specific for villin found in patients with colon cancer and other colitides

D. Rimm, J. Morrow, James Anderson, 1995, Digestive diseases and sciences.

Deep learning trained on H&E tumor ROIs predicts HER2 status and Trastuzumab treatment response in HER2+ breast cancer

Jeffrey H. Chuang, D. Rimm, Emily S. Reisenbichler, 2021, bioRxiv.

Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype.

D. Rimm, M. Prasad, A. Psyrri, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Tissue Age Affects Antigenicity and Scoring for the 22C3 Immunohistochemistry Companion Diagnostic Test.

D. Rimm, Aileen I. Fernandez, Patricia Gaule, 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

R. Herbst, D. Zelterman, D. Rimm, 2018, Nature Communications.

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group.

Sarah N. Dudgeon, A. Beck, T. Nielsen, 2020, NPJ breast cancer.

Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer

D. Rimm, B. Ács, V. Bossuyt, 2019, npj Breast Cancer.

Definition of a direct extracellular interaction between Met and E‐cadherin

D. Rimm, G. Reshetnikova, Sergei Troyanovsky, 2007, Cell biology international.

Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group

J. Hartman, P. V. van Diest, C. Denkert, 2021, Cancers.

Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC).

R. Herbst, D. Rimm, Joseph K. McLaughlin, 2014 .

Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer

A. Madabhushi, D. Rimm, K. Schalper, 2023, NPJ precision oncology.

Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma.

Liron Pantanowitz, David L Rimm, Douglas J Hartman, 2018, Oral oncology.

Abstract S5-4: EGFR expression measured by quantitative immunofluorescense is associated with decreased benefit from trastuzumab in the adjuvant setting in the NCCTG (Alliance) N9831 trial.

D. Rimm, J. Gralow, K. Ballman, 2012 .

Immunocytochemical analysis of breast cells obtained by ductal lavage

D. Rimm, B. Haffty, B. King, 2002, Cancer.

What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study

M. Iorio, D. Rimm, P. Nuciforo, 2021, Cancer medicine.

AQUA analysis of thymidylate synthase reveals localization to be a key prognostic biomarker in 2 large cohorts of colorectal carcinoma.

D. Rimm, R. Camp, A. Molinaro, 2008, Archives of pathology & laboratory medicine.

b -Catenin Dysregulation in Thyroid Neoplasms Down-Regulation, Aberrant Nuclear Expression, and CTNNB1 Exon 3 Mutations Are Markers for Aggressive Tumor Phenotypes and Poor Prognosis

D. Rimm, R. Camp, G. Tallini, 2001 .

[Letter to the Editor] The need for improved education and training in research antibody usage and validation practices.

David L Rimm, Andrew R M Bradbury, Darryl Davis, 2016, BioTechniques.

Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial

G. Hortobagyi, L. Pusztai, D. Rimm, 2023, NPJ breast cancer.

Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease.

D. Rimm, A. Muzikansky, A. Mercurio, 2005, Cancer research.

Performance Comparison of Different Analytic Methods in Proficiency Testing for Mutations in the BRAF, EGFR, and KRAS Genes: A Study of the College of American Pathologists Molecular Oncology Committee.

Annette S. Kim, J. Merker, A. Rai, 2019, Archives of pathology & laboratory medicine.

Coexpression of β1,6-N-Acetylglucosaminyltransferase V Glycoprotein Substrates Defines Aggressive Breast Cancers with Poor Outcome

D. Rimm, R. Camp, R. Dickson, 2005, Cancer Epidemiology Biomarkers & Prevention.

Macrodissection prior to Closed System RT-qPCR is not necessary for Estrogen Receptor and HER2 Concordance with IHC/FISH in Breast Cancer

D. Rimm, V. Bossuyt, M. Bates, 2018, Laboratory Investigation.

MA15.06 Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC)

R. Herbst, D. Zelterman, D. Rimm, 2017 .

Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.

L. Pusztai, T. Qing, D. Rimm, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases

D. Rimm, C. Garbe, M. Röcken, 2023, EBioMedicine.

Quantitative examination of mechanophysical tumor cell enrichment in fine‐needle aspiration specimens

D. Rimm, L. Ernst, 2002, Cancer.

Survival in Breast Cancer High HSP 90 Expression Is Associated with Decreased Updated

Y. Kluger, D. Rimm, J. Giltnane, 2007 .

Measuring Faculty Effort: A Quantitative Approach That Aligns Personal and Institutional Goals in Pathology at Yale

Joanna A Gibson, D. Rimm, J. Sinard, 2021, Academic pathology.

Abstract 5557: Mutation analysis of melanoma tumor samples from ECOG 2603 clinical trial

K. Flaherty, J. Kirkwood, K. Nathanson, 2012 .

Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors

L. Pusztai, D. Rimm, A. Chagpar, 2021, npj Breast Cancer.

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer

L. Pusztai, T. Qing, D. Rimm, 2021, npj Breast Cancer.

Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology

A. Madabhushi, D. Rimm, K. Schalper, 2019, Nature reviews. Clinical oncology.

Can Mol Sub Fac

Adrian V. Lee, S. McDonald, D. Rimm, 2010 .

Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray.

D. Rimm, B. Haffty, D. Carter, 2004, Cancer journal.

Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

D. Rimm, A. Psyrri, E. Kyrodimos, 2023, Cancer research communications.

Tissue microarrays: leaping the gap between research and clinical adoption.

D. Rimm, M. Dolled-Filhart, M. Gustavson, 2013, Personalized medicine.

Deep learning-based cross-classifications reveal conserved spatial behaviors within tumor histological images

Jeffrey H. Chuang, D. Rimm, J. Noorbakhsh, 2020, Nature Communications.

Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer

Rajarsi R. Gupta, N. Halama, J. A. van der Laak, 2023, The Journal of pathology.

Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer

N. Halama, J. A. van der Laak, N. Rajpoot, 2023, The Journal of pathology.

Bimodal population or pathologist artifact?

David L Rimm, D. Rimm, J. Giltnane, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A possible association of human papilloma virus with a subset of colorectal adenocarcinomas.

D. Rimm, R. Camp, G. Chung, 2004, Journal of Clinical Oncology.

Quantitative analysis of estrogen receptor heterogeneity in breast cancer.

D. Rimm, R. Camp, G. Chung, 2007, Laboratory investigation; a journal of technical methods and pathology.

Quantitative in situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy with 111-in-Pentetreotide

D. Rimm, G. Chung, J. Murren, 2005 .

What are the biggest challenges and opportunities for biorepositories in the next three to five years?

S. Terry, D. Rimm, F. Betsou, 2010, Biopreservation and biobanking.

"Lineage addiction" in human cancer: lessons from integrated genomics.

Ashton C. Berger, M. Meyerson, W. Sellers, 2005, Cold Spring Harbor symposia on quantitative biology.

PD-1/PD-L1 interaction and CD25/FOXP3+ t cells to predict survival benefit from adjuvant chemotherapy in early stage non–small-cell lung cancer (ES-NSCLC).

J. Bordeaux, D. Rimm, K. Schalper, 2018 .

Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.

P. Jänne, D. Nguyen, D. Rimm, 2023, Cancer cell.

Atypical reparative change on cervical/vaginal smears may be associated with dysplasia

W. Frable, D. Rimm, Stephen Gmitro, 1996, Diagnostic cytopathology.

Not all well-differentiated cutaneous squamous cell carcinomas are equal: Tumors with disparate biologic behavior have differences in protein expression via digital spatial profiling.

C. Ko, D. Rimm, J. McNiff, 2022, Journal of the American Academy of Dermatology.

Expression of a candidate cadherin in T lymphocytes.

D. Rimm, M. Brenner, K. Cepek, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Gene Silencing in Skin After Deposition of Self-Delivery siRNA With a Motorized Microneedle Array Device

Christopher H Contag, David L Rimm, Tycho Speaker, 2013, Molecular therapy. Nucleic acids.

Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases

S. Signoretti, T. Choueiri, D. Djureinovic, 2023, Journal for ImmunoTherapy of Cancer.

The utility of Ki-ras mutation analysis in the cytologic diagnosis of pancreatobiliary neoplasma.

D. Rimm, D. Dillon, G. Tallini, 2000, Cancer journal.

Mark A. Rubin, Arul M. Chinnaiyan, David L. Rimm, 2004, The American journal of pathology.

ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC

D. Rimm, G. Mcmahon, V. Neumeister, 2017, PloS one.

Construction and Validation of Tissue Microarrays of Ductal Carcinoma In Situ and Terminal Duct Lobular Units Associated With Invasive Breast Carcinoma

M. García-Closas, M. Sherman, J. Lissowska, 2006, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue / Veronique M Neumeister;Fabio Parisi;Allison M England;Summar Siddiqui;Valsamo Anagnostou;Elizabeth Zarrella;Maria Vassilakopolou;Yalai Bai;Sasha Saylor;Anna Sapino;Yuval Kluger;David G

Y. Kluger, D. Rimm, A. Sapino, 2022 .

Quantitative Determination of Expression of the Prostate Cancer Protein (cid:1) -Methylacyl-CoA Racemase Using Automated Quantitative Analysis (AQUA) A Novel Paradigm for Automated and Continuous Biomarker Measurements

M. Rubin, A. Chinnaiyan, R. Kuefer, 2004 .

A Tissue Quality Index – an Intrinsic Control for Measurement of Effects of Pre-analytical Variables on FFPE Tissue

Y. Kluger, D. Rimm, A. Sapino, 2014, Laboratory Investigation.

Expression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast Cancer

Y. Kluger, D. Rimm, R. Camp, 2008, Clinical Cancer Research.

Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma

D. Rimm, R. Camp, H. Kluger, 2010, Clinical Cancer Research.

Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer

Dafydd G. Thomas, D. Rimm, K. Schalper, 2018, npj Breast Cancer.

GOLPH3 modulates mTOR signaling and rapamycin sensitivity in cancer

L. Chin, A. Protopopov, Yonghong Xiao, 2009, Nature.

Microvessel area using automated image analysis is reproducible and is associated with prognosis in breast cancer.

D. Rimm, R. Camp, Catherine A.W. Sullivan, 2009, Human pathology.

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

C. Sotiriou, S. Loi, L. Pusztai, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Receptor protein tyrosine phosphatase PTPmu associates with cadherins and catenins in vivo

D. Rimm, S. Brady-Kalnay, N. Tonks, 1995, The Journal of cell biology.

Quantitative image analysis of VEGF expression on a breast cancer tissue microarray

D. Rimm, R. Camp, G. Chung, 2005 .

Dynamic Interaction of Ptp ␮ with Multiple Cadherins in Vivo

D. Rimm, S. Brady-Kalnay, N. Tonks, 1998 .

Receptor Protein Tyrosine Phosphatase Ptplx Associates with Cadherins and Catenins in Vivo

D. Rimm, S. Brady-Kalnay, N. Tonks, 1994 .

The Expression of p12Octn Protein in Breast Cancer Is Independent of a- and 13-Catenin and E-Cadherin

D. Rimm, D. Dillon, T. D'Aquila, 2007 .

Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts

L. Harris, D. Rimm, R. Camp, 2011, Breast Cancer Research.

D. Rimm, F. Rosen, A. Forastiere, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

University of Birmingham Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer

Rajarsi R. Gupta, J. D. Hansen, N. Halama, 2023 .

Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study

R. Schiff, P. Neven, J. Mackey, 2011, Clinical Cancer Research.

False-positive pathology: improving reproducibility with the next generation of pathologists

D. Rimm, R. Homer, Benjamin L. Mazer, 2019, Laboratory Investigation.

The expression of p120ctn protein in breast cancer is independent of alpha- and beta-catenin and E-cadherin.

D. Rimm, E. Fearon, D. Dillon, 1998, The American journal of pathology.

Calcium Sensor, NCS-1, Promotes Tumor Aggressiveness and Predicts Patient Survival

D. Rimm, Barbara E. Ehrlich, Lauren M. Moore, 2017, Molecular Cancer Research.

CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers

L. Pusztai, D. Rimm, K. Schalper, 2018, Breast Cancer Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Ki67 reproducibility using digital image analysis: an inter-platform and inter-operator study

S. Leung, T. Nielsen, D. Rimm, 2018, Laboratory Investigation.

A Pathway for the Control of Anoikis Sensitivity by E-Cadherin and Epithelial-to-Mesenchymal Transition

B. Cieply, D. Rimm, Fan Zhang, 2011, Molecular and Cellular Biology.

A prospective, multi-institutional diagnostic trial to determine pathologist accuracy in estimation of percentage of malignant cells.

D. Rimm, M. Hameed, K. Halling, 2013, Archives of pathology & laboratory medicine.

Analytic Variability in Immunohistochemistry Biomarker Studies

K. Syrigos, D. Rimm, J. Giltnane, 2010, Cancer Epidemiology, Biomarkers & Prevention.

Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review

D. Rimm, Taja Ložar, C. Grašič Kuhar, 2023, Viruses.

Stress Keratin 17 Is a Predictive Biomarker Inversely Associated with Response to Immune Check-Point Blockade in Head and Neck Squamous Cell Carcinomas and Beyond

D. Rimm, Huy Q. Dinh, Taja Ložar, 2023, Cancers.

Prediction of distant melanoma recurrence from primary tumor digital H&E images using deep learning.

D. Rimm, B. Ács, R. Phelps, 2019, Journal of Clinical Oncology.

Cytoplasmic Estrogen Receptor in Breast Cancer

R. Schiff, M. Sherman, Chungyeul Kim, 2011, Clinical Cancer Research.

Immune Checkpoint Inhibitor-Associated Pericarditis.

R. Herbst, D. Rimm, S. Gettinger, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Assessment of the Impact of Alternative Fixatives on HER2 Detection in Breast Cancer and Gastric Cancer Tumor Specimens

D. Rimm, J. Cogswell, T. Kuwata, 2023, Applied immunohistochemistry & molecular morphology : AIMM.

Degree of dysplasia following diagnosis of atypical squamous cells of undetermined significance is influenced by patient history and type of follow‐up

D. Rimm, Rola A. D. Ghoussoub, 1997, Diagnostic cytopathology.

Macrophage expression of tartrate-resistant acid phosphatase as a prognostic indicator in colon cancer

D. Rimm, Jason R. Brown, J. How, 2014, Histochemistry and Cell Biology.

Spectral Analysis of Breast Cancer on Tissue Microarrays: Seeing Beyond Morphology

D. Rimm, 2004 .

Obesity and heredity in the etiology of non-insulin-dependent diabetes mellitus in 32,662 adult white women.

R. D. Morris, D. Rimm, R. Morris, 1989, American journal of epidemiology.